Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session - NSCLC, metastatic 1

LBA46 - Efficacy and safety of poziotinib in treatment-naïve NSCLC harboring HER2 exon 20 mutations: A multinational phase II study (ZENITH20-4)


18 Sep 2021


Proffered Paper session - NSCLC, metastatic 1


Cytotoxic Therapy;  Clinical Research

Tumour Site

Non-Small Cell Lung Cancer


Robin Cornelissen


Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741


R. Cornelissen1, S. Sun2, M. Wollner3, M.C.C. Garassino4, A. Prelaj5, E.B. Haura6, Z. Piotrowska7, J.W. Goldman8, M. Socinski9, L. Dreling10, G. Bhat11, F. Lebel12, X. Le13

Author affiliations

  • 1 Pulmonary Medicine, Erasmus MC - University Medical Center, 3015 CE - Rotterdam/NL
  • 2 Medical Oncology, British Columbia Cancer center, V5Z4E6 - Vancouver/CA
  • 3 Medical Oncology, Rambam Health Care Campus, 3109601 - Haifa/IL
  • 4 Department Of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Medicine, Section of Hematology/Oncolog, Knapp Center for Biomedical Discovery, The University of Chicago, 60637 - Chicago/US
  • 5 Medical Oncology, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, 20133 - Milan/IT
  • 6 Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa/US
  • 7 Cancer Center, Massachusetts General Hospital, Boston/US
  • 8 Medicine, Hematology & Oncology, David Geffen School of Medicine at UCLA, Los Angeles/US
  • 9 Medical Oncology, AdventHealth Cancer Institute, 32803 - Orlando/US
  • 10 Clinical Research, Spectrum Pharmaceuticals, 92618 - Irvine/US
  • 11 Clinical Science Department, Spectrum Pharmaceuticals, 92618 - Irvine/US
  • 12 Research & Development, Spectrum Pharmaceuticals, 92618 - Irvine/US
  • 13 Department Of Thoracic Head And Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston/US


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract LBA46


Treatment of non-small cell lung cancer (NSCLC) with EGFR and HER2 exon 20 mutations is an unmet medical need. We evaluated the efficacy and safety of poziotinib, a potent tyrosine kinase inhibitor (TKI) able to overcome the restricted binding pocket of exon 20 mutations, in newly diagnosed patients with NSCLC and HER2 exon 20 insertion mutations in a multinational, multi-cohort Phase 2 study.


ZENITH20 study enrolled pts with advanced NSCLC with exon 20 insertion mutations: previously treated EGFR, previously treated HER2, naïve EGFR and naïve HER2 in Cohorts 1, 2, 3, and 4 respectively as identified by genetic profiling of tumor tissue. Poziotinib (16 mg) was administered orally daily either as once (QD) or twice (BID), allowing dose interruptions/reductions for toxicity. The primary endpoint was objective response rate (ORR) evaluated centrally by an independent image review committee using RECIST 1.1 criteria. Secondary endpoints included disease control rate (DCR), duration of response (DOR), progression-free survival (PFS) and safety. Data from Cohort 4 is presented.


48 received 16 mg QD and 23 received 8 mg BID in Cohort 4. QD data is presented; BID dosing group is currently enrolling. In QD group, 48 patients with a median age of 61 years (34-87) were treated and 4 patients are ongoing in the study. Majority were White (75%), female (54%), non-smokers (69%) with ECOG PS of 1 (65%). 88% patients had dose interruptions and 76% had reductions from 16 mg starting dose. 12% had AE related discontinuations. The most common treatment-related Grade ≥3 AEs were rash (35%), diarrhea (14%), stomatitis (20%) and paronychia (8%). Primary endpoint ORR was 44% (95% CI: 29.5 – 58.8%) in the 48 treated patients. 2 additional patients had response not confirmed (uORR=48%). DCR was 75%. Median DoR was 5.4 months (range: 2.8-19.1+) with 3 patients continuing treatment. Median PFS was 5.6 months (range: 0-20.2+).


Poziotinib demonstrated clinically meaningful efficacy in newly diagnosed NSCLC patients with HER2 exon 20 mutations with 16 mg QD dosing. Safety profile was similar to other second generation TKIs with manageable AEs. Study is ongoing with BID dosing currently.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Spectrum Pharmaceuticals, inc.


Spectrum Pharmaceuticals.


L. Dreling: Financial Interests, Institutional, Full or part-time Employment: Spectrum Pharmaceuticals. G. Bhat: Financial Interests, Institutional, Full or part-time Employment: Spectrum Pharmaceuticals. F. Lebel: Financial Interests, Institutional, Full or part-time Employment: Spectrum Pharmaceuticals. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.